The COVID-19 front is a fast-moving beast!
The sooner we announce something along the lines on, who “we are currently in discussions with <sic> about a possible clinical trial in human patients with ARDS, including those who have developed ARDS as a result of thedevastating COVID-19 pandemic” and when… the better!
Imagine what an announcement this afternoon stating that a Large Pharma and Cynata have approval from the FDA to trial Cymerus MSCs on a number of NYC patients with ARDS would do…
We can only wonder at this stage... if Ross is capable of any such thing!
Ann: Cynata MSCs beneficial in preclinical ARDS study, page-10
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $39.74M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.5¢ | 22.0¢ | $29.06K | 131.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 951 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 15.59pm 08/11/2024 (20 minute delay) ? |
| CYP (ASX) Chart |